RC Nelson
Founder & Editor
RC Nelson is the founder and editor of GLP1 Clinics, the largest U.S. directory of NPI-verified GLP-1 weight loss providers. He leads the team that maintains the 9,700+ clinic database, the Trust Score methodology, and the Dose news desk, and writes about GLP-1 medication access, drug pricing, insurance coverage, and provider comparisons. Based in Detroit, Michigan.
Areas of Expertise
Articles by RC Nelson
Orforglipron: Lilly's Oral GLP-1 Pill, Cost, and Launch Timeline
Lilly's once-daily oral GLP-1 is on track for late-2026 FDA approval. The ATTAIN-1 phase 3 trial showed about 14% weight loss without injections, food restrictions, or peptide manufacturing. Here's what's known about cost, launch timing, and how it stacks up.
Zepbound and Pregnancy: The 2-Month Washout Rule (2026 Guide)
Why Lilly's label says to stop Zepbound 2 months before conception, the oral contraceptive interaction window most patients don't hear about, and exactly what to do if you find out you're pregnant on tirzepatide.
Major Study Shows GLP-1 Drugs Cut Heart and Kidney Disease Risk in Type 1 Diabetes
Johns Hopkins analysis of 175,000 Type 1 diabetes patients shows GLP-1 drugs reduce heart disease risk by 15% and kidney failure by 19% without safety concerns.
GLP-1 Supplements: The Truth About 'Natural Ozempic' in 2026
Berberine, ACV gummies, fiber blends, 'GLP-1 boosting' probiotics. What the science actually says about these so-called natural Ozempic alternatives, what they cost, and when (if ever) they make sense.
Novo Nordisk Launches Ozempic Pill in US with $149 Starting Price
Novo Nordisk's Ozempic pill launches May 4 with self-pay pricing starting at $149/month, offering the first oral diabetes option under the Ozempic brand.
GLP-1 Microdosing: A 2026 Guide to Lower-Dose Semaglutide and Tirzepatide
What GLP-1 microdosing actually is, why patients are using semaglutide and tirzepatide at 25-50% of the standard dose, what the limited data shows, and how to do it safely with a prescriber.
Hidden Fees of GLP-1 Telehealth: What to Watch for Before You Sign Up
Investigative breakdown of the hidden fees buried in GLP-1 telehealth subscriptions: setup fees, dose escalation surcharges, shipping minimums, cancellation costs, and add-ons that can double your monthly bill.
FDA Plans July Meeting to Ease Peptide Restrictions After RFK Jr. Push
RFK Jr.'s peptide advocacy leads FDA to schedule July meetings on lifting Biden-era restrictions for compounding pharmacies, potentially opening new wellness treatment access.
GLP-1 Cost by State: Where Weight Loss Treatment Is Cheapest and Most Expensive
State-by-state analysis of GLP-1 medication and clinic pricing across the US. Where care costs the least, where it costs the most, and how telehealth equalizes access regardless of where you live.
How Much Does Mounjaro Cost in 2026? Diabetes Coverage, Off-Label Weight Loss, and Cash-Pay
Complete 2026 breakdown of Mounjaro (tirzepatide) pricing for diabetes and off-label weight loss: list price, Lilly savings programs, insurance coverage, telehealth alternatives, and the cheapest paths.
How Much Does Wegovy Cost in 2026? Insurance, Coupons, and Cash-Pay Pricing
Complete 2026 breakdown of Wegovy (semaglutide) pricing: list price, Novo Nordisk savings programs, insurance coverage, telehealth alternatives, and the cheapest legitimate paths to lower your monthly cost.
Brand-Name vs Compounded GLP-1: Cost Breakdown & What to Watch For
Compounded GLP-1 medications cost up to 80% less than brand-name versions. Here's the full cost comparison, the FDA shortage rules that allow compounding, and the trade-offs every patient should understand.
Novo's Oral Semaglutide First to Show Promise for Kids with Type 2 Diabetes
Novo Nordisk's PIONEER TEENS trial shows oral semaglutide reduced blood sugar by 0.83% in kids aged 10-17, potentially becoming the first oral GLP-1 for pediatric diabetes.
How Much Does Zepbound Cost in 2026? Insurance, Coupons, and Cash-Pay Pricing
A complete breakdown of Zepbound (tirzepatide) pricing in 2026: list price, savings programs, insurance coverage, telehealth alternatives, and ways to lower your monthly cost.
Novo Nordisk Files First-Ever Dual GLP-1/Amylin Drug for FDA Review
CagriSema combines semaglutide with a novel amylin receptor agonist, achieving 23% weight loss in trials and representing the first dual-mechanism GLP-1 therapy to seek approval.
Microdosing Tirzepatide: Why Some Patients Split Their Weekly Dose
The FDA has been cracking down on compounded GLP-1 medications. One of the strongest arguments for keeping the compounded option is something the branded weekly pen literally cannot do: microdosing across multiple smaller injections per week.
GLP-1 Medications Are Quietly Restoring Male Fertility — Here's What the Data Shows
A urologist published a case last week of a man who increased his sperm count tenfold after losing 100 pounds on tirzepatide. It's not an isolated story. The link between metabolic disease and male infertility is one of the least-discussed reasons GLP-1 medications matter.
The 100 Highest-Rated GLP-1 Clinics in America (2026 Rankings)
The 100 top-scoring GLP-1 weight-loss clinics in our directory of 9,700+ US providers, ranked by our v1.0.0 Trust Score. Full methodology and 100-clinic list.
Best GLP-1 Clinics in Detroit: Pricing, Insurance, and What to Expect (2026)
A Detroit-native guide to the local GLP-1 clinic landscape: Henry Ford, Corewell, east-side medspas, Oakland County boutiques, Michigan Medicaid 2026 changes, and what the 313 actually pays for semaglutide and tirzepatide.
GLP-1 Pioneers Propose Radical Shift: Drop GLP-1 Entirely for Weight Loss
Researchers behind today's GLP-1 obesity drugs suggest targeting GLP-1 may not be necessary, proposing GIP/glucagon dual agonist that could match weight loss with fewer side effects.
Lilly Responds to FDA Safety Request with Foundayo Heart Trial Data
Eli Lilly released cardiovascular safety data for Foundayo just days after FDA demanded additional studies on potential heart and liver risks.
Foundayo Hits Pharmacies as FDA Demands Additional Safety Data From Eli Lilly
Eli Lilly's new oral GLP-1 pill Foundayo launched in US pharmacies this week, but the FDA is requiring new safety studies for cardiovascular risks and other concerns.
Retatrutide Delivers Record 2% A1C Drop and 16.8% Weight Loss in Diabetes Trial
Eli Lilly's triple-agonist retatrutide achieved up to 2% A1C reduction and 36.6 pounds of weight loss in its first Phase 3 diabetes trial, marking a potential new standard for type 2 diabetes treatment.
Genetics May Predict Your GLP-1 Drug Response, Landmark Study Shows
New 23andMe research identifies genetic variants that explain why some people lose 20% of their weight on GLP-1s while others see minimal results.
First Generic GLP-1 Hits Market as Liraglutide Shortage Continues
Generic liraglutide becomes first GLP-1 with generic availability, offering hope for lower costs while brand shortage persists.
FDA Delays Orforglipron Decision to April Amid Priority Voucher Program Setbacks
The FDA pushed back Eli Lilly's highly anticipated oral GLP-1 pill decision by two weeks to April 10, marking the first major delays in the new priority review program.
Four States Drop GLP-1 Obesity Coverage as Federal Expansion Model Launches
California, Pennsylvania, New Hampshire, and South Carolina eliminated Medicaid GLP-1 obesity coverage in January 2026, reducing state coverage from 16 to 13 states despite new federal BALANCE model.
The Best Online GLP-1 Providers in 2026: An In-Depth Comparison of 10 Platforms
We evaluated 10 telehealth GLP-1 platforms across pricing, medications, insurance, clinical quality, and patient experience. Here are the results — from the $99/month budget option to the specialist-led programs.
Major Insurers Adding GLP-1 Coverage as Employer Demand Surges in 2026
UnitedHealthcare, Cigna, and Aetna have expanded GLP-1 weight management coverage for employer-sponsored plans in 2026, driven by corporate demand and emerging data on healthcare cost savings.
Three States Expand Telehealth Prescribing Rules for Weight Loss Medications
California, Texas, and Florida have enacted new regulations that make it easier for clinicians to prescribe GLP-1 medications through telehealth platforms, removing prior in-person visit requirements.
SELECT Trial Follow-Up Confirms Lasting Cardiovascular Benefits of Semaglutide
A two-year follow-up analysis of the landmark SELECT trial shows semaglutide's cardiovascular protection persists and may strengthen over time, with a 23% reduction in major cardiac events.
Novo Nordisk Breaks Ground on $4.1 Billion Manufacturing Facility in North Carolina
Novo Nordisk has begun construction on a $4.1 billion fill-finish manufacturing campus in Johnston County, North Carolina, expected to create 2,000 jobs and triple U.S. production capacity.
FDA Sends Warning Letters to 21 Compounding Pharmacies Over Semaglutide Quality
The FDA has issued warning letters to 21 compounding pharmacies citing quality failures in their semaglutide products, including incorrect potency and sterility violations.
Retatrutide Phase 3 Trial Results Show 24% Average Body Weight Reduction
Eli Lilly's triple-hormone receptor agonist retatrutide achieved 24.2% weight loss in a pivotal Phase 3 trial, the largest reduction seen in any obesity drug study to date.